BR0316599A - Agentes de alvejamento anti-linfoma com funções efetoras e de afinidade ligadas por um reagente trifuncional - Google Patents

Agentes de alvejamento anti-linfoma com funções efetoras e de afinidade ligadas por um reagente trifuncional

Info

Publication number
BR0316599A
BR0316599A BR0316599-0A BR0316599A BR0316599A BR 0316599 A BR0316599 A BR 0316599A BR 0316599 A BR0316599 A BR 0316599A BR 0316599 A BR0316599 A BR 0316599A
Authority
BR
Brazil
Prior art keywords
effector
lymphoma
targeting agents
reagent
functions linked
Prior art date
Application number
BR0316599-0A
Other languages
English (en)
Inventor
Bengt Sandberg
Rune Nilsson
Original Assignee
Mitra Medical Technology Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0203731A external-priority patent/SE0203731D0/xx
Application filed by Mitra Medical Technology Ab filed Critical Mitra Medical Technology Ab
Publication of BR0316599A publication Critical patent/BR0316599A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1084—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
    • A61K51/109—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin immunoglobulins having two or more different antigen-binding sites or multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"AGENTES DE ALVEJAMENTO ANTI-LINFOMA COM FUNçõES EFETORAS E DE AFINIDADE LIGADAS POR UM REAGENTE TRIFUNCIONAL". Um agente medicinal compreendendo um reagente conjugado a um anticorpo anti-linfoma é descrito, bem como um kit contendo o referido agente medicinal, uso do referido agente medicinal, e um método para tratamento de linfomas. O reagente pode compreender um efetor, por exemplo, um agente antitumor ou um marcador diagnóstico, e um ligando de afinidade possibilitando depuração extracorpórea do agente. Os três componentes são ligados por um ligador trifuncional.
BR0316599-0A 2002-12-13 2003-12-12 Agentes de alvejamento anti-linfoma com funções efetoras e de afinidade ligadas por um reagente trifuncional BR0316599A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43301202P 2002-12-13 2002-12-13
SE0203731A SE0203731D0 (sv) 2002-12-13 2002-12-13 Reagent
PCT/SE2003/001949 WO2004054615A1 (en) 2002-12-13 2003-12-12 Antilymphoma targeting agents with effector and affinity functions linked by a trifunctional reagent

Publications (1)

Publication Number Publication Date
BR0316599A true BR0316599A (pt) 2005-10-04

Family

ID=32599441

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0316599-0A BR0316599A (pt) 2002-12-13 2003-12-12 Agentes de alvejamento anti-linfoma com funções efetoras e de afinidade ligadas por um reagente trifuncional

Country Status (11)

Country Link
EP (1) EP1569690B1 (pt)
JP (1) JP2006511532A (pt)
KR (1) KR20050086907A (pt)
AU (1) AU2003287131B2 (pt)
BR (1) BR0316599A (pt)
CA (1) CA2509103A1 (pt)
MX (1) MXPA05006306A (pt)
NO (1) NO20052842L (pt)
PL (1) PL377213A1 (pt)
RU (1) RU2005122033A (pt)
WO (1) WO2004054615A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110045005A1 (en) 2001-10-19 2011-02-24 Craig Crowley Compositions and methods for the treatment of tumor of hematopoietic origin
PT2161283E (pt) * 2003-11-17 2014-08-29 Genentech Inc Composições que compreendem anticorpos contra cd79b conjugados a um agente de inibição do crescimento ou agente citotóxico e métodos para o tratamento de tumor de origem hematopoiética
FR2875410B1 (fr) 2004-09-23 2012-11-16 Guerbet Sa Composes de diagnostique pour le ciblage de recpteur a chimiokines
KR100699278B1 (ko) * 2005-05-12 2007-03-23 학교법인 포항공과대학교 수화젤레이터로 유용한 바이오틴-아미노산 결합체 및이로부터 제조된 수화젤
DK2215117T4 (en) 2007-10-30 2018-04-09 Genentech Inc ANTISTO PURIFICATION BY CATION CHANGE CHROMATOGRAPHY
EP3320912B1 (en) 2008-04-17 2021-03-31 IO BIOTECH ApS Indoleamine 2, 3-dioxygenase based immunotherapy
JP5563572B2 (ja) * 2008-07-23 2014-07-30 ハンミ サイエンス カンパニー リミテッド 三末端官能基を有する非ペプチド性重合体を用いた生理活性ポリペプチド薬物結合体
NO331080B1 (no) * 2010-01-29 2011-09-26 Nordic Nanovector As Radioimmunkonjugater, farmasøytiske sammensetninger og kit omfattende det samme og anvendelse derav
CA3101613A1 (en) * 2018-05-31 2019-12-05 George Mason Research Foundation, Inc. Organometallic labels for the detection of biomolecules, methods of synthesis and processes for conjugating an organometallic labels to a biomolecule
JPWO2022224980A1 (pt) 2021-04-20 2022-10-27
KR20230119859A (ko) * 2022-02-08 2023-08-16 연세대학교 산학협력단 신규 이중타겟 융합항체를 유효성분으로 포함하는 암의 예방 또는 치료용 조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010023288A1 (en) * 1999-07-07 2001-09-20 Wilbur D. Scott Trifunctional reagent for conjugation to a biomolecule
WO2000002050A1 (en) * 1998-07-07 2000-01-13 Department Of Radiation Oncology, University Of Washington Trifunctional reagent for conjugation to a biomolecule
DK1974747T3 (da) * 1998-08-11 2012-09-17 Biogen Idec Inc Kombinationsterapier for B-celle-lymfomer omfattende indgivelse af anti-CD20-antistof
CA2405632A1 (en) * 2000-04-25 2001-11-01 Idec Pharmaceutical Corporation Intrathecal administration of rituximab for treatment of central nervous system lymphomas

Also Published As

Publication number Publication date
CA2509103A1 (en) 2004-07-01
AU2003287131B2 (en) 2008-07-24
WO2004054615A1 (en) 2004-07-01
NO20052842L (no) 2005-09-12
NO20052842D0 (no) 2005-06-13
AU2003287131A1 (en) 2004-07-09
EP1569690B1 (en) 2011-07-27
JP2006511532A (ja) 2006-04-06
KR20050086907A (ko) 2005-08-30
PL377213A1 (pl) 2006-01-23
RU2005122033A (ru) 2006-01-27
EP1569690A1 (en) 2005-09-07
MXPA05006306A (es) 2005-09-21

Similar Documents

Publication Publication Date Title
PT1157041E (pt) Anticorpos para terapia e diagnostico de cancro
NO20052842L (no) Antilymfom malrettede midler med effektor og affinitetsfunksjoner linket av en trifunksjonell reagent
BRPI0111220B8 (pt) conjugados de fármacos com etilenodicisteína (ec)
CR8428A (es) Agente endoparasiticidas para la administracion topica
BRPI0412975A (pt) espuma penetrante para uso farmacêutico
BR9911482A (pt) Composto, composição farmacêutica, uso do composto, e, processos para o tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto
BR0206985A (pt) Anticorpos modificados e métodos de uso
BR0111358A (pt) Compostos de tioacetamida e seu uso
BR0211550A (pt) Derivados de triazolil-imidazopiridina e das triazolilpurinas úteis como ligandos do receptor a2a da adenosina, e seu uso como medicamentos
BRPI0416928A (pt) desenvolvimento de derivados biologicamente ativos de azul de metileno
ATE448232T1 (de) Substituierte heterozyklen
BRPI0414858A (pt) métodos para preparação de corpos de óleo compreendendo ingredientes ativos
TR199800443T1 (xx) Hidroliz y�kseltici taksan hidrofobik t�revleri.
BRPI0409359A (pt) análogos quiméricos de somatostatina-dopamina
TR200201245T2 (tr) Kanser tedavisi için onkolitik kombinasyonlar.
BR0311491A (pt) Composto, composição farmacêutica, uso de um composto, e, método terapêutico para tratar câncer em um mamìfero
ES2144054T3 (es) Complejos de tri(platino).
ME00624B (me) Nova primjena docetaksela za liječenje hepatoma
BR0306732A (pt) Tratamentos em combinação para doença alérgica compreendendo a administração de um anticorpo anti-ige e composto antialérgico
BR0314716A (pt) Anticorpos de subunidade alfa de lfa-1 e métodos de uso
SE0203731D0 (sv) Reagent
BR0111669A (pt) Novos compostos
BR0111726A (pt) Derivados de biotina
SE0002287D0 (sv) Biotinderivat
BR0009194A (pt) Composição do resorcinol

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 5A, 6A E 7A ANUIDADE(S).

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2073 DE 28/09/2010.

B15K Others concerning applications: alteration of classification

Ipc: A61K 51/10 (2006.01), A61K 47/60 (2017.01), A61K 4